There was insufficient evidence to support the use of oral fish oil (on its own or in the presence of other treatments) for the management of the weight loss syndrome often seen in patients with advanced cancer. Many people with advanced cancer develop a distressing weight loss syndrome. To date, treatment of associated symptoms has proved difficult. More recently, novel approaches have included the use of oral fish oils that can contain the omega-3 fatty acid eicosapentaenoic acid (or EPA) to stabilise weight loss and promote weight gain. This review of trials found that in weight losing persons with advanced pancreatic cancer, an EPA nutritional supplement was no better than a non EPA nutritional supplement. However, there was insufficient evidence to draw conclusions about its use in patients who have cancer of other tumour types.
Vollständige Zusammenfassung lesen
Cancer cachexia is a distressing weight loss syndrome commonly seen in advanced cancer patients. It is associated with reduced quality of life and shorter survival time. Eicosapentaenoic acid (EPA) is a long chain polyunsaturated fatty acid found naturally in some fish which has been used to decrease weight loss, promote weight gain and increase survival times in patients affected with cancer cachexia.
Zielsetzungen
To evaluate the effectiveness and safety of EPA in relieving symptoms associated with the cachexia syndrome in patients with advanced cancer.
Suchstrategie
Studies were sought through an extensive search of a range of electronic databases. Hand searching was conducted on selected journals and reference lists as well as contact made with investigators, manufacturers and experts. The most recent electronic search was conducted in February 2005.
Auswahlkriterien
Studies were included in the review if they assessed oral EPA compared with placebo or control in randomised controlled trials of patients with advanced cancer and either a clinical diagnosis of cachexia or self-reported weight loss of 5% or more.
Datensammlung und ‐analyse
Both methodological quality evaluation of potential trials and data extraction were conducted by two independent review authors.
Hauptergebnisse
Five trials (involving 587 participants) met the inclusion criteria. Three trials compared EPA at different doses with placebo with two outcomes, nutritional status and adverse events comparable across two of the three included trials. In addition, two trials compared different doses of EPA with an active matched control. It was possible to compare the outcomes of weight, quality of life and adverse events across these two trials. There were insufficient data to define the optimal dose of EPA.
Schlussfolgerungen der Autoren
There were insufficient data to establish whether oral EPA was better than placebo. Comparisons of EPA combined with a protein energy supplementation versus a protein energy supplementation (without EPA) in the presence of an appetite stimulant (Megestrol Acetate) provided no evidence that EPA improves symptoms associated with the cachexia syndrome often seen in patients with advanced cancer.
